Dilawar Khan, MD
Hematology & Oncology · Rome, GANPI 1588725188
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,076 of the $56,892 with a category attached, or 70.4%. It is spread thinly across 39 manufacturers, the largest accounting for just 20.2%. Reporting peaked in 2023 at $18,725 and has fallen 99.4% since, to $117 in 2025. Among hematology & oncology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $360.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$11K
- AstraZeneca$8K
- Genentech USA, Inc.$7K
- Eisai Inc.$5K
- Deciphera Pharmaceuticals Inc.$5K
- GSK$4K
- plus $17K from 33 others
Across 14 payments — averaging $1415.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$14K
- Incyte Corporation$4K
- Helsinn Healthcare SA$2K
- Eli Lilly$73
What the payments were for
- Consulting fees$40,07670%
- Speaking & faculty fees$8,29915%
- Travel & lodging$4,1517%
- Food & beverage$4,0837%
- Education$2840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 21 | $11,466 |
| AstraZeneca | 16 | $7,949 |
| Genentech USA, Inc. | 6 | $6,946 |
| Eisai Inc. | 11 | $4,880 |
| Deciphera Pharmaceuticals Inc. | 13 | $4,791 |
| GSK | 7 | $4,236 |
| Novartis | 13 | $2,982 |
| Novocure Inc. | 1 | $2,600 |
| AbbVie | 6 | $2,476 |
| Gilead(2 entities) | 3 | $1,334 |
| Pfizer | 17 | $1,331 |
| Epizyme, Inc. | 1 | $1,250 |
| Bayer | 1 | $1,221 |
| Daiichi Sankyo Inc. | 2 | $675 |
| Beigene USA, Inc. | 1 | $525 |
| EMD Serono, Inc. | 1 | $500 |
| Beigene, Ltd. | 1 | $450 |
| Johnson & Johnson | 3 | $262 |
| Foundation Medicine, Inc. | 1 | $149 |
| Puma Biotechnology, Inc. | 2 | $140 |
| Mirati Therapeutics, Inc. | 1 | $125 |
| Exelixis Inc. | 2 | $96 |
| Novo Nordisk | 4 | $95 |
| Astellas Pharma US Inc | 3 | $58 |
| Taiho Oncology, Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $41 |
| Amgen | 2 | $32 |
| Merck | 1 | $23 |
| US Oncology Corporate, Inc. | 1 | $22 |
| Janssen Scientific Affairs, LLC | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Intuitive Surgical | 1 | $16 |
| Incyte Corporation | 1 | $14 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
| Array Biopharma Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,892 in reported general payments places this provider in the 90th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 88 | $1,529,562 |
| Lenalidomide | 69 | $989,813 |
| XtandiEnzalutamide | 66 | $752,862 |
| TagrissoOsimertinib Mesylate | 40 | $656,826 |
| KisqaliRibociclib Succinate | 36 | $432,955 |
| CalquenceAcalabrutinib Maleate | 20 | $421,835 |
| NubeqaDarolutamide | 35 | $419,697 |
| TepmetkoTepotinib Hcl | 12 | $293,271 |
| PomalystPomalidomide | 12 | $280,767 |
| IbrancePalbociclib | 13 | $211,922 |
| PromactaEltrombopag Olamine | 11 | $210,817 |
| JakafiRuxolitinib Phosphate | 12 | $207,740 |
| BrukinsaZanubrutinib | 12 | $163,133 |
| VenclextaVenetoclax | 20 | $131,904 |
| Imatinib Mesylate | 23 | $57,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $7,949 | $1,078,66160 claims |
| Astellas Pharma US IncXtandi | $58 | $752,86266 claims |
| NovartisKisqali, Promacta | $2,982 | $643,77347 claims |
| BayerNubeqa | $1,221 | $419,69735 claims |
| EMD Serono, Inc.Tepmetko | $500 | $293,27112 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $43 | $280,76712 claims |
| PfizerIbrance, Eliquis | $1,331 | $221,05330 claims |
| Incyte CorporationJakafi | $14 | $207,74012 claims |
| AbbVieVenclexta, Creon | $2,476 | $164,91339 claims |
| Beigene USA, Inc.Brukinsa | $525 | $163,13312 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $22 | $12,25435 claims |
| Johnson & JohnsonXarelto | $262 | $9,43211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Rome
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
- Abdullah KutlarAugusta$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.